/
ATAI
$5.36+$0.07 (+1.32%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.9B
368M shares
52-week range
$2.16 – $6.75
70% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
1.39%
Moderate
Price (6 mo)
Loading chart…
Change$-13.14
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $20.4M | $233.0K | $314.0K | $308.0K | $4.1M |
| Cost of revenue | $6.0K | $24.0K | $47.0K | $168.0K | $319.0K | $473.0K | $1.0M |
| Gross profit | −$6.0K | −$24.0K | $20.3M | $65.0K | −$5.0K | −$165.0K | $3.1M |
| Gross margin | — | — | 99.8% | 27.9% | -1.6% | -53.6% | 75.3% |
| R&D | $12.8M | $23.4M | $47.9M | $74.1M | $61.9M | $55.0M | $53.1M |
| Operating income | −$17.8M | −$104.2M | −$120.3M | −$144.4M | −$125.5M | −$102.7M | −$99.8M |
| EBITDA | −$17.8M | −$104.1M | −$178.2M | −$150.1M | −$39.9M | −$147.3M | −$657.7M |
| Net income | −$14.1M | −$169.8M | −$167.8M | −$152.4M | −$40.2M | −$149.3M | −$660.0M |
| Net margin | — | — | -823.6% | -65401.3% | -12810.2% | -48464.0% | -16142.0% |
| EPS (diluted) | -0.09 | -1.11 | -1.04 | -0.98 | -0.25 | -0.93 | -2.91 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-0.43 | $-0.70–$-0.31 | 9 |
| 2027 | $671727 | $-0.45 | $-0.52–$-0.36 | 7 |
| 2028 | $2M | $-0.45 | $-0.65–$-0.18 | 12 |
| 2029 | $74M | $-0.33 | $-0.52–$-0.24 | 10 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.19
Price
$5.36
Implied downside
-97%
Peer comparison
AtaiBeckley Inc. Common Stock
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
www.ataibeckley.com- Employees
- 99
- IPO / List date
- Jun 18, 2021
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds ATAI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ATAI as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ATAI yet.
